Fluidigm Corporation (NASDAQ:FLDM) Director Samuel D. Colella purchased 35,895 shares of the business’s stock in a transaction dated Tuesday, August 8th. The stock was purchased at an average price of $2.77 per share, for a total transaction of $99,429.15. Following the completion of the acquisition, the director now owns 45,197 shares of the company’s stock, valued at $125,195.69. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Fluidigm Corporation (NASDAQ FLDM) opened at 3.09 on Wednesday. The company’s market capitalization is $90.52 million. The stock has a 50 day moving average price of $3.84 and a 200-day moving average price of $5.08. Fluidigm Corporation has a one year low of $2.52 and a one year high of $9.65.

Fluidigm Corporation (NASDAQ:FLDM) last issued its earnings results on Thursday, August 3rd. The medical research company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.02. The company had revenue of $23.90 million during the quarter, compared to the consensus estimate of $23.50 million. Fluidigm Corporation had a negative return on equity of 104.38% and a negative net margin of 74.05%. The firm’s revenue for the quarter was down 15.2% compared to the same quarter last year. During the same period last year, the business posted ($0.63) EPS. On average, equities research analysts expect that Fluidigm Corporation will post ($2.19) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Fluidigm Corporation (FLDM) Director Samuel D. Colella Purchases 35,895 Shares” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/09/fluidigm-corporation-fldm-director-samuel-d-colella-purchases-35895-shares.html.

A number of analysts have recently commented on the company. Zacks Investment Research lowered Fluidigm Corporation from a “hold” rating to a “sell” rating in a report on Friday, May 12th. ValuEngine lowered Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

Several hedge funds have recently modified their holdings of the stock. American International Group Inc. increased its stake in shares of Fluidigm Corporation by 7.1% in the first quarter. American International Group Inc. now owns 17,907 shares of the medical research company’s stock valued at $102,000 after buying an additional 1,187 shares in the last quarter. Levin Capital Strategies L.P. increased its stake in shares of Fluidigm Corporation by 0.6% in the first quarter. Levin Capital Strategies L.P. now owns 5,789,282 shares of the medical research company’s stock valued at $32,941,000 after buying an additional 33,529 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Fluidigm Corporation by 20.5% in the first quarter. Bank of New York Mellon Corp now owns 206,578 shares of the medical research company’s stock valued at $1,175,000 after buying an additional 35,176 shares in the last quarter. Falcon Point Capital LLC increased its stake in shares of Fluidigm Corporation by 3.1% in the first quarter. Falcon Point Capital LLC now owns 40,661 shares of the medical research company’s stock valued at $231,000 after buying an additional 1,238 shares in the last quarter. Finally, Stoneridge Investment Partners LLC increased its stake in shares of Fluidigm Corporation by 4.2% in the first quarter. Stoneridge Investment Partners LLC now owns 25,293 shares of the medical research company’s stock valued at $144,000 after buying an additional 1,013 shares in the last quarter. Institutional investors own 91.66% of the company’s stock.

Fluidigm Corporation Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.